Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease

NEUROBIOLOGY OF AGING

卷:106

Article

Pfeil, Julia¹  Hoenig, Merle C.^1,2  Doering, Elena^1,3  van Eimeren, Thilo^1,3,4  Drzezga, Alexander^1,2,3  Bischof, Gerard N.¹ 

[1] Univ Cologne, Univ Hosp Cologne, Dept Nucl Med, Multimodal Neuroimaging Grp, Kerpenerstr 62, D-50931 Cologne, Germany

[2] Mol Org Brain, Res Ctr Juelich, Inst Neurosci & Med 2, Julich, Germany

[3] German Ctr Neurodegenerat Dis, Bonn, Germany

[4] Univ Cologne, Univ Hosp Cologne, Dept Neurol, Cologne, Germany

关键词: Alzheimer's disease;    Mild cognitive impairment;    Regional amyloid burden;    Positron emission tomography;    Disease progression;    Amyloid-beta;   

DOI  :  10.1016/j.neurobiolaging.2021.06.014

来源: Elsevier

【 摘 要 】

Although beta-amyloid (A beta) positivity has shown to be associated with higher risk of progression to Alzheimer's disease (AD) in mild cognitive impairment (MCI), information on the time to conversion to manifest dementia cannot be readily deduced from this binary classification. Here, we assessed if regional patterns of A beta deposition measured with F-18-florbetapir may serve as biomarker for progression risk in A beta-positive cognitively normal (CN) and MCI patients, including clinical follow-up data and cerebrospinal fluid (CSF) biomarkers. Voxel-wise group comparisons between age and sex-matched A beta-positive groups (i.e., CN-stables [n = 38] vs. CN-to-MCI/AD progressors [n = 38], MCI-stables [n = 104] versus MCI-toAD progressors [n = 104]) revealed higher A beta burden in precuneus, subcortical, and parietal regions in CN-to-MCI/AD progressors and cingulate, temporal, and frontal regions in MCI-to-AD progressors. Importantly, these regional patterns predicted progression to advanced stages on the AD spectrum in the short and the long-term beyond global A beta burden and CSF biomarkers. These results suggest that distinct regional patterns of A beta burden are a valuable biomarker for risk of disease progression in CN and MCI. (C) 2021 The Authors. Published by Elsevier Inc.

【 授权许可】

Free